ESR1 and neoplasm: In a very clear recommendation, postmenopausal patients with low-grade and/or low-genomic signature ER-positive, HER2-negative tumours with an indication for neoadjuvant treatment, the vast majority (98%) of the panel voted in favour of neoadjuvant ET (NET) [6].